Renovorx, Inc. (RNXT) Stock Price & Analysis
Renovorx, Inc. (RNXT) fell 2.89% to USD 0.86 as of June 10, 2026 at 06:47 UTC, according to Nexqual real-time market data.
RNXT last closed at USD 0.89; the session ranged USD 0.86–0.9 on volume of 165,142 shares. Market capitalization is $38.79M, with a 52-week range of USD 0.7–1.45 (NCM). Source: Nexqual, June 10, 2026 at 06:47 UTC.
Key Statistics (as of June 10, 2026 at 06:47 UTC)
| Price | USD 0.86 |
|---|---|
| Change | ▼ 2.89% (down) |
| Previous Close | USD 0.89 |
| Open | USD 0.89 |
| Day Range | USD 0.86 – 0.9 |
| 52-Week Range | USD 0.7 – 1.45 |
| Volume | 165,142 shares |
| Market Cap | $38.79M |
| Exchange | NCM |
Technical Analysis (RNXT)
Nexqual's technical model rates RNXT "NEUTRAL" based on 2 bullish and 3 bearish signals across 123 daily candles, as of June 10, 2026 at 06:47 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 47.63 (neutral) |
| vs SMA50 | Below (USD 0.92) |
| MACD | 0 (positive) |
Analyst Ratings (RNXT)
Wall Street analysts rate RNXT "Strong Buy" based on 4 analysts, with a mean price target of USD 7.03 (range USD 3–14), per Nexqual as of June 10, 2026 at 06:47 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 7.03 |
| High Target | USD 14 |
| Low Target | USD 3 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (RNXT)
| EPS Estimate | USD -0.08 |
|---|---|
| Revenue Estimate | $703,750 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.08 vs est -0.08 ▼ miss |
| 2025-12-31 | USD -0.08 vs est -0.08 ▲ beat |
| 2025-09-30 | USD -0.08 vs est -0.08 ▲ beat |
| 2025-06-30 | USD -0.08 vs est -0.08 ▲ beat |
Source: Nexqual, June 10, 2026 at 06:47 UTC.
Financials & Fundamentals (RNXT)
| Total Revenue | $1.49M |
|---|---|
| Revenue Growth (YoY) | +185.80% |
| Gross Margin | +78.71% |
| Operating Margin | -616.16% |
| Profit Margin | +0.00% |
| ROE | -100.48% |
| Debt / Equity | 1.65 |
| Current Ratio | 7.15 |
| Total Cash | $12.36M |
| Total Debt | $186,000 |
| Free Cash Flow | $-6.45M |
Source: Nexqual, June 10, 2026 at 06:47 UTC.
Financial Health Score (RNXT)
Nexqual rates Renovorx, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 06:47 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $12M cash, no debt |
| Cash Flow | Weak — FCF negative: -$6M, burning cash |
| Efficiency | Critical — ROE -100%, ROA -51.6% |
Ownership (RNXT)
| Insider Ownership | +3.77% |
|---|---|
| Institutional Ownership | +19.01% |
| Shares Outstanding | 45.10M |
| Float | 39.87M |
| Short % of Float | +0.95% |
Source: Nexqual, June 10, 2026 at 06:47 UTC.
Leadership (RNXT)
Renovorx, Inc. is led by Shaun R. Bagai (age 48), CEO, Secretary & Director, per Nexqual as of June 10, 2026 at 06:47 UTC.
| CEO, Secretary & Director | Shaun R. Bagai (age 48) |
|---|---|
| Founder, Executive Chairman & Chief Medical Officer | Ramtin Agah (age 59) |
| CFO & Principal Accounting Officer | Mark Voll (age 70) |
| Vice President of Operations and R & D | Robert Strasser |
Major Backers & Investors (RNXT)
Notable institutional backers of Renovorx, Inc. include AIGH Capital Management LLC, Bleichroeder LP, Fidelity, according to Nexqual as of June 10, 2026 at 06:47 UTC.
Active Investors
| Investor | Stake |
|---|---|
| AIGH Capital Management LLC | 8.22% |
| Bleichroeder LP | 3.69% |
| Fidelity | 0.73% |
| Wealthspire Advisors, LLC | 0.56% |
| Citadel | 0.52% |
| Nixon Peabody Trust Company | 0.22% |
| Northwestern Mutual Wealth Management Company | 0.22% |
| Chicago Partners Investment Group LLC | 0.2% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 6.77% |
| Geode Capital | 0.85% |
Source: Nexqual, June 10, 2026 at 06:47 UTC.
From Renovorx, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- In addition, we have obtained FDA clearance for our RenovoCath delivery system, which is subject to FDA medical device regulations, including the Quality System Regulation.
- We obtain our RenovoCath delivery system from a single source, which must be manufactured in accordance with the FDA Quality System Regulation (QSR).
Partnerships
- Our failure to achieve and maintain these high-quality manufacturing standards in collaboration with our third-party manufacturers, including the incidence of manufacturing errors, could result in patient injury or death, product recalls or withdrawals, delays or failures in product testing or delivery, cost overruns or other problems that could harm our business, financial condition and results of operations.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| EVAX | Evaxion A/S | USD 3.63 | ▲ 2.25% |
| ABVC | ABVC Biopharma, Inc. | USD 1.32 | ▼ 0.75% |
| VRPX | Virpax Pharmaceuticals, Inc. | USD 0 | ▲ 0% |
| KTTA | Pasithea Therapeutics Corp. | USD 0.58 | ▼ 0.85% |
| INDP | Indaptus Therapeutics, Inc. | USD 2.03 | ▼ 44.67% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 06:47 UTC. This page is informational and not investment advice.